Skip to main content

Table 2 Demographic, clinical and MRI characteristics, and lipid profiles of patient subsets with and without statins.

From: Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis

Variable

No Statins

Statins

p-value

Females: Males (% Female)

301: 81 (78.8%)

69: 40 (63.3%)

< 0.002§

MS course:

  

0.075‡

Relapsing-remitting

314

81 (74.3%)

 

Secondary progressive

(82.2%)

  

Primary progressive

55 (12.8%)

13 (3.4%)

27 (24.8%)

1 (0.9%)

 

Age*, years

45.3 ± 10.7

53.4 ± 8.4

< 0.001

Disease duration*, years

11.9 ± 9.7

16.2 ± 11.0

< 0.001

Median EDSS* (IQR)

2.5 (2.0)

3.50 (3.50)

< 0.001#

MSSS

3.67 ± 2.51

4.15 ± 2.18

0.061

Time to follow-up, years

2.13 ± 1.0

2.22 ± 1.0

0.43

Body mass index, kg/m2

27.4 ± 6.5

29.1 ± 6.5

0.013¶

HDL, mg/dL

55.6 ± 16.6

53.7 ± 16.5

0.72¶

LDL, mg/dL

115 ± 30.8

118 ± 39.0

0.62¶

Total cholesterol, mg/dL

196 ± 36.0

201 ± 44.7

0.38¶

Triglycerides, mg/dL

128 ± 84.0

149 ± 75.5

0.15¶

Cholesterol to HDL ratio

3.81 ± 1.28

4.00 ± 1.40

0.60¶

Presence of CEL

CEL number

CE-LV, cm3

25/156 (16%)

0.60 ± 2.3

0.035 ± 0.15

4/40 (10%)

0.23 ± 0.86

0.019 ± 0.080

0.47¶

0.026¶

0.035¶

T2-LV, cm3

13.6 ± 14.7

16.0 ± 14.7

0.30¶

T1-LV, cm3

2.7 ± 5.1

4.5 ± 6.3

0.019¶

BPF

0.858 ± 0.027

0.848 ± 0.035

0.056¶

  1. Statin usage data were available for 491 patients.
  2. * At time of baseline lipid profile assessment.
  3. § Fisher exact test
  4. ‡ Fisher exact test for presence of secondary progressive or progressive forms of MS.
  5. # Mann-Whitney test
  6. ¶ p-values for statin variable from regression analyses with sex, disease duration and statin use as predictor variables.